WO2026071086A1 - Peptide, complexe peptidique, composition pour culture cellulaire, composition pour utilisation dans le domaine médical, du diagnostique ou de la recherche, et procédé de production d'un complexe peptidique - Google Patents

Peptide, complexe peptidique, composition pour culture cellulaire, composition pour utilisation dans le domaine médical, du diagnostique ou de la recherche, et procédé de production d'un complexe peptidique

Info

Publication number
WO2026071086A1
WO2026071086A1 PCT/JP2025/034127 JP2025034127W WO2026071086A1 WO 2026071086 A1 WO2026071086 A1 WO 2026071086A1 JP 2025034127 W JP2025034127 W JP 2025034127W WO 2026071086 A1 WO2026071086 A1 WO 2026071086A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
amino acid
residue
peptides
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/JP2025/034127
Other languages
English (en)
Japanese (ja)
Inventor
芳典 鈴木
翔 澤田
尚三 本田
憲宏 柴田
克磨 松井
基 桑原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peptidream Inc
Original Assignee
Peptidream Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptidream Inc filed Critical Peptidream Inc
Publication of WO2026071086A1 publication Critical patent/WO2026071086A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Ce peptide comprend une séquence d'acides aminés représentée par la formule A1 ou une séquence d'acides aminés dans laquelle un ou plusieurs résidus d'acides aminés dans la séquence d'acides aminés représentée par la formule A1 ont été substitués, supprimés, ajoutés ou insérés. A1 : X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15
PCT/JP2025/034127 2024-09-27 2025-09-26 Peptide, complexe peptidique, composition pour culture cellulaire, composition pour utilisation dans le domaine médical, du diagnostique ou de la recherche, et procédé de production d'un complexe peptidique Pending WO2026071086A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2024169014 2024-09-27
JP2024-169014 2024-09-27

Publications (1)

Publication Number Publication Date
WO2026071086A1 true WO2026071086A1 (fr) 2026-04-02

Family

ID=99308457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2025/034127 Pending WO2026071086A1 (fr) 2024-09-27 2025-09-26 Peptide, complexe peptidique, composition pour culture cellulaire, composition pour utilisation dans le domaine médical, du diagnostique ou de la recherche, et procédé de production d'un complexe peptidique

Country Status (1)

Country Link
WO (1) WO2026071086A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
WO2024195709A1 (fr) * 2023-03-17 2024-09-26 富士フイルム株式会社 Peptide cyclique ou sel de celui-ci et son utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
WO2024195709A1 (fr) * 2023-03-17 2024-09-26 富士フイルム株式会社 Peptide cyclique ou sel de celui-ci et son utilisation

Similar Documents

Publication Publication Date Title
JP7780253B2 (ja) ステープルペプチドの細胞内送達のためのポリペプチド接合体
WO2021041895A1 (fr) Ligands de bêta-caténine agrafés
KR20240082377A (ko) 펩티드
WO2017217545A1 (fr) Régulateur de liaison de la plexine
EP4180446A1 (fr) Peptide cyclique, complexe peptidique et composition médicamenteuse contenant ledit peptide cyclique et/ou ledit complexe peptidique
CN113024635B (zh) 一类订书肽化合物及其药物组合物的用途
CN115768456A (zh) Tslp特异性的双环肽配体
US10562935B2 (en) Stapled peptides and uses thereof
WO2026071086A1 (fr) Peptide, complexe peptidique, composition pour culture cellulaire, composition pour utilisation dans le domaine médical, du diagnostique ou de la recherche, et procédé de production d'un complexe peptidique
EP4501941A1 (fr) Complexe peptidique ayant une activité de liaison trkb
KR102043992B1 (ko) Ncoa1/stat6 단백질-단백질 상호작용을 저해하는 신규 스테이플 펩타이드 및 이의 용도
WO2021070920A1 (fr) Peptide cyclique
US20250326865A1 (en) C-met protein-binding peptide complex
WO2025197823A1 (fr) Peptide, complexe peptidique, composition pharmaceutique, composition pour culture cellulaire et composition à usage médical, utilisation diagnostique ou utilisation de recherche
KR20260062945A (ko) Vegfr-2 작용제 활성을 가지는 펩타이드 복합체
WO2025047927A1 (fr) Complexe peptidique ayant une activité agoniste de vegfr-2
HK40109184A (zh) 具有trkb结合活性的肽复合物
TW202542175A (zh) 人類介白素(il)-17細胞激素結合肽
WO2026080980A1 (fr) Inhibiteurs et leurs utilisations
WO2025100520A1 (fr) Peptide, complexe peptidique, composition pharmaceutique, composition pour culture cellulaire, et composition mise en œuvre dans le traitement médical, le diagnostic ou la recherche
JP2025532958A (ja) ＥｐｈＡ２結合保留ペプチド及びそれを含む組成物
AU2024361525A1 (en) Inhibitors and uses therefor
WO2025081231A1 (fr) Inhibiteurs et leurs utilisations
JP2024523280A (ja) Ｇｈｒ結合ペプチドおよびそれを含む組成物
HK40096428A (zh) C-met蛋白结合肽复合物